The headlines are screaming about a "deadly surge" of tuberculosis in the United States. They want you to believe we are on the precipice of a Victorian-era plague. They point to the 16% jump in cases reported by the CDC in 2023—reaching 9,622 cases—as proof that the sky is falling.
It isn’t.
This isn't a resurgence of a dormant monster; it's a predictable data correction. If you’ve spent any time in the trenches of public health surveillance, you know that numbers without context are just ghost stories. The "rise" in TB isn't an outbreak. It's the sound of a system finally catching up after three years of COVID-induced paralysis.
Stop looking at the percentage increase and start looking at the baseline. We are witnessing the death rattles of a disease that has already lost its grip on the American landscape, yet we continue to fund the panic rather than the solution.
The Post-Pandemic Data Mirage
The "deadliest infectious disease" narrative relies on you forgetting that the world effectively shut down in 2020. For three years, people stopped going to the doctor for chronic coughs. Health departments diverted every single TB investigator to contact tracing for COVID-19.
The 2023 "surge" is simply the clinical manifestation of a massive backlog. These aren't new infections hitting the streets yesterday; these are the latent cases and the missed diagnoses of 2021 and 2022 finally hitting the ledger.
When you look at the raw data, the 9,622 cases in 2023 still hover near record lows when compared to the 1990s, where cases routinely topped 25,000. To call this a "rise" is technically true but intellectually dishonest. It’s like saying a drought is over because it rained for twenty minutes.
The Myth of Universal Vulnerability
The most dangerous lie being pushed by mainstream health reporting is that TB is an "equal opportunity" threat to the average American. It isn't.
Tuberculosis in the U.S. is a highly localized, demographic-specific issue. Roughly 76% of cases occur in non-U.S.-born individuals. This isn't a xenophobic talking point; it's a biological reality. The disease is being imported from regions where $Mycobacterium$ $tuberculosis$ remains endemic.
Yet, we treat our domestic response as if the general population is at risk. We waste millions on broad awareness campaigns when the high-yield strategy is surgical: targeted screening in immigrant communities and rigorous treatment of Latent TB Infection (LTBI).
If we actually wanted to "end TB," we would stop acting like every cough in a suburban Starbucks is a potential outbreak and put those resources into the clinics in Queens, Los Angeles, and Houston that are actually seeing the patients.
Why We Fail: The LTBI Paradox
We are obsessed with the "Active TB" case. It’s dramatic. It’s contagious. It’s easy to track. But active TB is just the tip of a very deep iceberg.
The real problem—the one the "experts" rarely talk about because it’s boring—is LTBI. Estimates suggest up to 13 million people in the U.S. have latent TB. They aren't sick. They aren't contagious. But they are the reservoir for every future case of active disease.
The current system is reactive. We wait for someone to start coughing blood, then we spend $20,000 to $500,000 on isolation, treatment, and contact tracing.
Imagine a scenario where we treated TB like a preventable structural failure rather than an accidental fire. Instead of waiting for the house to burn down, we would be aggressively treating the 13 million people carrying the "matches." But we don’t. Because testing 13 million people is expensive, and insurance companies hate paying for the "prevention" of a disease that might not manifest for thirty years.
The Boogeyman of Drug Resistance
You’ll hear a lot about MDR-TB (Multidrug-resistant TB). It’s the favorite scary story of the medical establishment. They’ll tell you that "superbugs" are going to render our antibiotics useless.
In the U.S., MDR-TB accounts for about 1% of cases.
One percent.
We have some of the best success rates in the world for treating resistant strains because we use DOT (Directly Observed Therapy). We literally send a health worker to your house to watch you swallow your pills. It’s intrusive, it’s expensive, and it works.
The narrative that we are losing the war to resistant bacteria ignores the fact that we have new tools like BPaL (Bedaquiline, Pretomanid, and Linezolid). We have shortened treatment for resistant TB from two years of toxic injections to six months of oral pills. The "crisis" of resistance is a global tragedy, but in the U.S., it’s a managed boutique problem.
The Cost of the Wrong Focus
Every dollar spent fear-mongering about a TB "rise" in the U.S. is a dollar not spent on the actual killers.
While we fret over 9,000 cases of TB (most of which are cured), we are ignoring the fact that syphilis rates have hit a 70-year high. We are ignoring the explosion of fungal infections in hospitals. We are ignoring the collapse of basic primary care access.
TB is a convenient distraction. It’s an "old world" disease that feels manageable. It has a clear protocol. It has dedicated funding lines. It’s easy to write a grant for TB. It’s much harder to address the systemic poverty and housing instability that actually drive its transmission.
Your Risks Are Miscalculated
If you are a healthy individual living in the U.S., your risk of contracting TB is effectively zero.
The people who are actually at risk—the unhoused, the incarcerated, and those living in crowded, multi-generational households in underserved areas—are the ones being failed by the "rise" narrative. When we frame this as a national threat, we dilute the focus needed for these specific groups.
We don't need "more awareness." We need better plumbing in the public health machine.
Stop Screening the Worried Well
The CDC and local health departments need to stop the theatre. We still see employers demanding TB skin tests for office workers who have never left the country. This is "hygiene theater" at its finest.
The Mantoux skin test is a relic. It’s prone to false positives, especially in people who had the BCG vaccine abroad. We should be using IGRAs (Interferon-Gamma Release Assays) exclusively, but they’re more expensive, so we stick to the 19th-century technology and wonder why our data is messy.
The Harsh Truth About "Eradication"
We will never "eradicate" TB in the United States as long as it exists anywhere else in the world.
Global travel ensures that. But "control" is not the same as "crisis." We have reached a point of diminishing returns in our current TB strategy. We are spending more and more to find fewer and fewer cases, while the headlines try to convince you we’re losing ground.
The "rise" is a glitch in the timeline, not a change in the trajectory.
Stop buying the panic. If you want to actually move the needle, stop looking for "surges" in the news and start looking at the funding gaps in community clinics.
The real danger isn't the bacteria. It’s the sensationalism that prevents us from seeing where the fire is actually burning.
Stop worrying about the 9,000. Start worrying about why we can't find the 13 million.
